Effectiveness of canakinumab for the treatment of patients with Yao syndrome

J Am Acad Dermatol. 2023 Mar;88(3):653-654. doi: 10.1016/j.jaad.2019.09.020. Epub 2019 Sep 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal* / adverse effects
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Chronic Disease
  • Humans
  • Interleukin-1beta
  • Treatment Outcome

Substances

  • canakinumab
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • Interleukin-1beta